Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3326971 | 0.84 | MAOA (0.47) | MAOAKDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL133421 | 0.78 | MAOA (0.57) | MAOAKDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL4336089 | 0.75 | CYP3A4 (0.53) | MAOAKDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL132462 | 0.73 | MAOA (1.00) | MAOAKDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL30668674 | 0.73 | MAOA (1.00) | MAOAKDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL3328856 | 0.72 | MAOA (0.56) | MAOAKDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL7068663 | 0.67 | CA12 (0.52) | MAOAKDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL22171903 | 0.66 | MAOA (0.58) | MAOAKDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL789119 | 0.66 | MAOA (1.00) | MAOAKDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL14443986 | 0.65 | MAOA (0.71) | MAOAKDM4ENPC1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137421-A1 | SMALL MOLECULE THERAPEUTICS, SYNTHESIS OF ANALOGUES AND DERIVATIVES AND METHODS OF USE | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2010-06-03 | — | — | US | claimed |
| WO-2008057604-A9 | SMALL MOLECULE THERAPEUTICS, SYNTHESES OF ANALOGUES AND DERIVATIVES AND METHODS OF USE | UNIV CALIFORNIA (US) | 2008-10-02 | — | — | WO | claimed |
| WO-2008057604-A2 | SMALL MOLECULE THERAPEUTICS, SYNTHESES OF ANALOGUES AND DERIVATIVES AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-05-15 | — | — | WO | claimed |
| US-8501803-B2 | Garcinia derivative, its preparing method and medicinal use | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2013-08-06 | — | — | US | disclosed |
| US-8501803-B2 | Garcinia derivative, its preparing method and medicinal use | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2013-08-06 | — | — | US | disclosed |
| EP-2494971-A1 | GAMBOGIC ACID DERIVATIVES, PREPARATIVE METHODS AND USES THEREOF | China Pharmaceutical University (CN) | 2012-09-05 | — | — | EP | disclosed |
| US-20120059050-A1 | GARCINIA DERIVATIVE, ITS PREPARING METHOD AND MEDICINAL USE | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2012-03-08 | — | — | US | disclosed |
| US-20120059050-A1 | GARCINIA DERIVATIVE, ITS PREPARING METHOD AND MEDICINAL USE | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2012-03-08 | — | — | US | disclosed |
| US-20100137421-A1 | SMALL MOLECULE THERAPEUTICS, SYNTHESIS OF ANALOGUES AND DERIVATIVES AND METHODS OF USE | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2010-06-03 | — | — | US | disclosed |
| US-20100137421-A1 | SMALL MOLECULE THERAPEUTICS, SYNTHESIS OF ANALOGUES AND DERIVATIVES AND METHODS OF USE | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2010-06-03 | — | — | US | disclosed |
| US-20100137421-A1 | SMALL MOLECULE THERAPEUTICS, SYNTHESIS OF ANALOGUES AND DERIVATIVES AND METHODS OF USE | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2010-06-03 | — | — | US | disclosed |
| US-7592143-B2 | Methods of treating diseases responsive to induction of apoptosis and screening assays | CYTOVIA, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| WO-2008057604-A9 | SMALL MOLECULE THERAPEUTICS, SYNTHESES OF ANALOGUES AND DERIVATIVES AND METHODS OF USE | UNIV CALIFORNIA (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008057604-A9 | SMALL MOLECULE THERAPEUTICS, SYNTHESES OF ANALOGUES AND DERIVATIVES AND METHODS OF USE | UNIV CALIFORNIA (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008057604-A2 | SMALL MOLECULE THERAPEUTICS, SYNTHESES OF ANALOGUES AND DERIVATIVES AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057604-A2 | SMALL MOLECULE THERAPEUTICS, SYNTHESES OF ANALOGUES AND DERIVATIVES AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-05-15 | — | — | WO | disclosed |
| EP-1620564-A4 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | CYTOVIA INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1620564-A2 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | Cytovia, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050004026-A1 | Methods of treating diseases responsive to induction of Apoptosis and screening assays | CYTOVIA, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004094647-A2 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | CYTOVIA, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137421-A1 | SMALL MOLECULE THERAPEUTICS, SYNTHESIS OF ANALOGUES AND DERIVATIVES AND METHODS OF USE | BAD, CASP3, BID | MAOA 3590/4885KDM4E 2993/4885NPC1 844/4885 |
| US-20120059050-A1 | GARCINIA DERIVATIVE, ITS PREPARING METHOD AND MEDICINAL USE | GLG1, GDI1, GYPA | MAOA 2460/4885KDM4E 834/4885NPC1 1305/4885 |
| US-20050004026-A1 | Methods of treating diseases responsive to induction of Apoptosis and screening assays | HEATR6, HEATR1, AIP | MAOA 4083/4885KDM4E 4490/4885NPC1 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.